PL2782557T3 - Formulacje farmaceutyczne - Google Patents

Formulacje farmaceutyczne

Info

Publication number
PL2782557T3
PL2782557T3 PL12809882T PL12809882T PL2782557T3 PL 2782557 T3 PL2782557 T3 PL 2782557T3 PL 12809882 T PL12809882 T PL 12809882T PL 12809882 T PL12809882 T PL 12809882T PL 2782557 T3 PL2782557 T3 PL 2782557T3
Authority
PL
Poland
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Application number
PL12809882T
Other languages
English (en)
Polish (pl)
Inventor
Daya Verma
Yogita Krishnamachari
Xiaohong SHEN
Hanchen LEE
Ping Li
Rajinder Singh
LayChoo TAN
Original Assignee
Array Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47501412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2782557(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma, Inc. filed Critical Array Biopharma, Inc.
Publication of PL2782557T3 publication Critical patent/PL2782557T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL12809882T 2011-11-23 2012-11-21 Formulacje farmaceutyczne PL2782557T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161563229P 2011-11-23 2011-11-23
PCT/US2012/066185 WO2013078264A1 (en) 2011-11-23 2012-11-21 Pharmaceutical formulations
EP12809882.9A EP2782557B1 (en) 2011-11-23 2012-11-21 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
PL2782557T3 true PL2782557T3 (pl) 2019-03-29

Family

ID=47501412

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12809882T PL2782557T3 (pl) 2011-11-23 2012-11-21 Formulacje farmaceutyczne

Country Status (38)

Country Link
US (4) US9387208B2 (OSRAM)
EP (2) EP2782557B1 (OSRAM)
JP (2) JP6216325B2 (OSRAM)
KR (1) KR102091295B1 (OSRAM)
CN (2) CN103945831A (OSRAM)
AR (1) AR088936A1 (OSRAM)
AU (1) AU2012340759C1 (OSRAM)
BR (1) BR112014011981B8 (OSRAM)
CA (1) CA2856406C (OSRAM)
CL (1) CL2014001337A1 (OSRAM)
CO (1) CO6940426A2 (OSRAM)
CY (1) CY1121421T1 (OSRAM)
DK (1) DK2782557T3 (OSRAM)
EA (1) EA025389B1 (OSRAM)
EC (1) ECSP23034537A (OSRAM)
ES (2) ES2695099T3 (OSRAM)
GT (1) GT201400100A (OSRAM)
HR (1) HRP20181896T1 (OSRAM)
HU (1) HUE040370T2 (OSRAM)
IL (1) IL232305B (OSRAM)
JO (1) JO3493B1 (OSRAM)
LT (1) LT2782557T (OSRAM)
MA (1) MA35716B1 (OSRAM)
MX (1) MX353446B (OSRAM)
MY (1) MY172729A (OSRAM)
PE (1) PE20141994A1 (OSRAM)
PH (1) PH12014501157A1 (OSRAM)
PL (1) PL2782557T3 (OSRAM)
PT (1) PT2782557T (OSRAM)
RS (1) RS58048B1 (OSRAM)
SG (1) SG11201401260QA (OSRAM)
SI (1) SI2782557T1 (OSRAM)
SM (1) SMT201800595T1 (OSRAM)
TN (1) TN2014000145A1 (OSRAM)
TW (1) TWI649098B (OSRAM)
UA (1) UA115039C2 (OSRAM)
WO (1) WO2013078264A1 (OSRAM)
ZA (1) ZA201402418B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
CA2855243C (en) 2011-11-11 2020-04-14 Novartis Ag Method of treating a proliferative disease
PE20141994A1 (es) 2011-11-23 2014-12-24 Novartis Ag Formulaciones farmaceuticas
EP3636283A1 (en) 2015-06-04 2020-04-15 Pfizer Inc Solid dosage forms of palbociclib
RU2615986C1 (ru) * 2016-02-25 2017-04-12 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения
US10449195B2 (en) * 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
WO2017210538A1 (en) 2016-06-03 2017-12-07 Giordano Caponigro Pharmaceutical combinations
CN106000220A (zh) * 2016-06-30 2016-10-12 东华大学 一种含化学试剂的有机溶剂崩解片的制备方法与应用
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022074011A1 (en) 2020-10-05 2022-04-14 Pierre Fabre Medicament Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma
CN114557977A (zh) * 2022-02-16 2022-05-31 北京康立生医药技术开发有限公司 一种治疗肠癌的药物的制备方法、制剂及纯度分析方法
WO2023239337A1 (en) * 2022-06-08 2023-12-14 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi A pharmaceutical composition comprising palbociclib
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5475888A (en) 1977-11-29 1979-06-18 Jiyasuko Kk Surgical laser
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
EP0952770A4 (en) 1995-09-07 1999-12-22 Fuisz Technologies Ltd SYSTEM FOR MAKING SUBSTANTIALLY NON-SOLUBLE BIOALTERANT AGENTS BIOAVAILABLE
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EP1000055A1 (en) 1997-05-22 2000-05-17 G.D. Searle & Co. SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
ME00275B (me) 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
JP5159012B2 (ja) 1999-12-23 2013-03-06 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド 不良溶解性の薬物に対する改良された医薬組成物
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
ATE374753T1 (de) 2001-12-21 2007-10-15 Vernalis Cambridge Ltd 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
RU2006128788A (ru) 2004-01-09 2008-02-20 Новартис АГ (CH) Производные фенил[4-(3-фенил-1н-пиразол-4-ил)пиримидин-2-ил] амина в качестве igf-1r ингибиторов
CA2567662C (en) 2004-06-10 2012-11-27 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2006279794B2 (en) 2005-08-12 2011-04-07 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate HSP90 activity
JP2009504796A (ja) * 2005-08-22 2009-02-05 ノバルティス アクチエンゲゼルシャフト ｐＨ依存性薬剤化合物、ｐＨ調整剤および遅延剤を含む医薬組成物
WO2007024843A2 (en) 2005-08-26 2007-03-01 Smithkline Beecham Corporation Pyrimidinyl-pyrazole inhibitors of aurora kinases
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
JP2009530261A (ja) 2006-03-16 2009-08-27 ファイザー・プロダクツ・インク ピラゾール化合物
WO2007123892A2 (en) 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
CN101522661A (zh) 2006-10-02 2009-09-02 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
CN101522026A (zh) 2006-10-06 2009-09-02 Irm责任有限公司 蛋白激酶抑制剂及其应用方法
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
KR20100038119A (ko) 2007-08-01 2010-04-12 화이자 인코포레이티드 피라졸 화합물 및 ｒａｆ 억제제로서 이의 용도
BRPI0818340A2 (pt) 2007-10-19 2015-04-22 Abbott Gmbh & Co Kg Produto de dispersão sólida de fármacos baseados em n-aril uréia
EP2220083B1 (en) 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
KR20130040258A (ko) 2008-03-21 2013-04-23 노파르티스 아게 신규한 헤테로시클릭 화합물 및 그의 용도
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
HRP20120577T1 (hr) 2008-07-24 2012-08-31 Nerviano Medical Sciences S.R.L. 3,4-diarilpirazoli kao inhibitori proteinskih kinaza
EP2326622A1 (en) 2008-07-28 2011-06-01 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
CA2738448A1 (en) 2008-09-29 2010-04-01 Boehringer Ingelheim International Gmbh New chemical compounds
CN102238945B (zh) * 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 药物制剂514
WO2010056662A1 (en) 2008-11-11 2010-05-20 University Of Washington Activated wnt-beta-catenin signaling in melanoma
JP5490137B2 (ja) 2008-12-19 2014-05-14 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ プロテインキナーゼ阻害薬としての二環式ピラゾール
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
JP5789602B2 (ja) 2009-06-15 2015-10-07 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ピリミジニルピロロピリジノン誘導体、これらの製造のための方法およびキナーゼ阻害剤としてのこれらの使用
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
BR112012017705B1 (pt) 2010-01-27 2020-03-24 Nerviano Medical Science S.R.L. Derivados de sulfonamidas de 3,4-diarilpirazóis como inibidores da proteína cinase
RU2639876C2 (ru) 2010-03-30 2017-12-25 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
WO2012016993A1 (en) 2010-08-03 2012-02-09 Nerviano Medical Sciences S.R.L. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
CN103442715A (zh) 2011-03-21 2013-12-11 瓦尔库里亚公司 包括hdac抑制剂以及类固醇的药用组合物及其用途
SG195141A1 (en) 2011-06-14 2013-12-30 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer suchas a myeloproliferative neoplasm
PE20141994A1 (es) 2011-11-23 2014-12-24 Novartis Ag Formulaciones farmaceuticas
AU2013343425A1 (en) 2012-11-08 2015-06-11 Novartis Ag Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases

Also Published As

Publication number Publication date
UA115039C2 (uk) 2017-09-11
ES2695099T3 (es) 2019-01-02
SG11201401260QA (en) 2014-07-30
CN105708819A (zh) 2016-06-29
EP2782557B1 (en) 2018-09-12
KR102091295B1 (ko) 2020-03-19
AU2012340759C1 (en) 2019-11-28
US9763941B2 (en) 2017-09-19
HUE040370T2 (hu) 2019-03-28
EA025389B1 (ru) 2016-12-30
MX353446B (es) 2018-01-12
PH12014501157B1 (en) 2014-08-11
SMT201800595T1 (it) 2019-01-11
TN2014000145A1 (en) 2015-09-30
AU2012340759B2 (en) 2016-04-28
BR112014011981A8 (pt) 2018-07-31
CO6940426A2 (es) 2014-05-09
AU2012340759A1 (en) 2014-05-29
WO2013078264A1 (en) 2013-05-30
CN103945831A (zh) 2014-07-23
US20160279129A1 (en) 2016-09-29
IL232305A0 (en) 2014-06-30
BR112014011981B1 (pt) 2020-11-17
ES3037966T3 (en) 2025-10-08
US20140309250A1 (en) 2014-10-16
PE20141994A1 (es) 2014-12-24
ECSP23034537A (es) 2023-08-31
TWI649098B (zh) 2019-02-01
MA35716B1 (fr) 2014-12-01
ZA201402418B (en) 2015-03-25
JP2015501808A (ja) 2015-01-19
AR088936A1 (es) 2014-07-16
MY172729A (en) 2019-12-11
PT2782557T (pt) 2018-11-26
US9387208B2 (en) 2016-07-12
IL232305B (en) 2019-06-30
BR112014011981A2 (pt) 2017-05-30
RS58048B1 (sr) 2019-02-28
CY1121421T1 (el) 2020-05-29
EP3449911B8 (en) 2025-07-23
MX2014006278A (es) 2014-07-09
JO3493B1 (ar) 2020-07-05
LT2782557T (lt) 2018-12-27
CA2856406C (en) 2020-06-23
CA2856406A1 (en) 2013-05-30
GT201400100A (es) 2017-09-28
BR112014011981B8 (pt) 2022-07-19
US20170202837A1 (en) 2017-07-20
EP3449911B1 (en) 2025-06-18
JP2018035171A (ja) 2018-03-08
NZ623628A (en) 2016-05-27
US10561654B2 (en) 2020-02-18
EA201491007A1 (ru) 2014-08-29
HRP20181896T1 (hr) 2019-02-22
CL2014001337A1 (es) 2014-10-24
EP3449911A1 (en) 2019-03-06
KR20140095500A (ko) 2014-08-01
PH12014501157A1 (en) 2014-08-11
CN105708819B (zh) 2020-12-29
TW201328722A (zh) 2013-07-16
EP2782557A1 (en) 2014-10-01
JP6216325B2 (ja) 2017-10-18
DK2782557T3 (en) 2018-12-10
US10258622B2 (en) 2019-04-16
US20190054086A1 (en) 2019-02-21
HK1197024A1 (en) 2015-01-02
SI2782557T1 (sl) 2019-02-28

Similar Documents

Publication Publication Date Title
AP3864A (en) Pharmaceutical composition
GB201113662D0 (en) Pharmaceutical compositions
AP3656A (en) Pharmaceutical compositions
ZA201308208B (en) Pharmaceutical compositions
GB201118232D0 (en) Pharmaceutical composition
ZA201407373B (en) Novel pharmaceutical formulations
SG10201604667YA (en) Pharmaceutical preparation
IL232305A0 (en) pharmaceutical preparations
GB201105298D0 (en) Pharmaceutical preparation
EP2731610A4 (en) PHARMACEUTICAL COMBINATION
GB201118181D0 (en) Pharmaceutical compositions
PL2691119T3 (pl) Preparat farmaceutyczny
EP2727593A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING NICORANDIL
EP2711010A4 (en) PHARMACEUTICAL COMPOSITION
HUP1100444A2 (en) Pharmaceutical composition
IL227905A0 (en) Toroidal pharmaceutical compositions
GB201110278D0 (en) Formulations
GB201111577D0 (en) Pharmaceutical formulations
GB201211403D0 (en) Pharmaceutical formulations
GB201211406D0 (en) Pharmaceutical formulations
ZA201309537B (en) Pharmaceutical composition comprising fexofedine
GB201012046D0 (en) Pharmaceutical formulations
GB201012047D0 (en) Pharmaceutical formulations
GB201119796D0 (en) Pharmaceutical comopounds
GB201107626D0 (en) Formulations